Destiny Pharma plc (“Destiny Pharma” or “the Company”) Significant clinical and commercial opportunity of NTCD-M3 confirmed by positive data from US research study and new market research US Department of […]
Friday January 21, 2022
Destiny Pharma Lancet Report
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Important Lancet report highlights growing threat of Antimicrobial Resistance with over one million deaths per year Destiny Pharma’s XF platform is delivering […]
Monday January 17, 2022
Strategy/Company/Ops Update
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Trading update and outlook for 2022 Brighton, United Kingdom, 17 January 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative […]